NBTX vs NCNA

Nanobiotix S.A. vs NuCana plc — Valuation Comparison 2026

NBTX

Biotechnology
Nanobiotix S.A.
Quality
5.0
out of 10
Value Trap
18
SAFE
Price
$40.41
Last close
Models
6/13
Active
VS

NCNA

Biotechnology
NuCana plc
Quality
1.7
out of 10
Value Trap
Price
$2.27
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType NBTX Fair ValueNBTX Upside NCNA Fair ValueNCNA Upside
Bayesian DCF Intrinsic $9.06 -77.6% $0.60 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $3.98 +85.3%
PWERM Option-Based $40.14 -0.7%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for NBTX vs NCNA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NBTX vs NCNA — Which Stock Is More Undervalued?

NBTX scores higher with a 5.0/10 quality rating vs NCNA's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Nanobiotix S.A. (NBTX) and NuCana plc (NCNA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NBTX currently trades at $40.41 with a QOC of 5.0/10, while NCNA trades at $2.27 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).